We have located links that may give you full text access.
Breeding in the fat-tailed dunnart following ovarian suppression with the gonadotrophin-releasing hormone agonist Lucrin ® Depot.
Reproduction, Fertility, and Development 2018 March
Lucrin Depot (AbbVie), a 1-month microsphere gonadotrophin-releasing hormone (GnRH) agonist preparation, was investigated as a potential agent to synchronise cycling in the fat-tailed dunnart (Sminthopsis crassicaudata). Forty-eight randomly selected females were treated with 5 or 10mgkg-1 Lucrin Depot (n=24 per dose). Eighteen females per treatment had their reproductive activity scored at 4, 8, 12 and 16 weeks using two ovarian (Graafian follicle and corpus luteum status) and two reproductive tract (uterine and vaginal muscularity and vascularity) parameters that formed a reproductive activity score. Six females per treatment were paired with a male at 4 weeks. Fertility was assessed between 8 and 16 weeks by pouch check, and thereafter by dissection. The effects of the 5 and 10mgkg-1 doses were statistically equivalent. Females showed suppression at 4-8 weeks, an increase in reproductive activity at 8-12 weeks and all were cycling normally at 16 weeks. Six pouch young were born at 12 weeks to two females treated with the 5mgkg-1 dose. Nine embryos were recovered at 16 weeks from two females treated with the 10mgkg-1 dose. In conclusion, Lucrin Depot can suppress breeding, and fertile mating can occur in subsequent cycles in the dunnart. There is potential for Lucrin Depot to be used as an assisted breeding tool, but it may need to be combined with ovarian stimulation treatment to achieve practical levels of synchronisation in the fat-tailed dunnart.
Full text links
Related Resources
Trending Papers
Heart failure with preserved ejection fraction: diagnosis, risk assessment, and treatment.Clinical Research in Cardiology : Official Journal of the German Cardiac Society 2024 April 12
Proximal versus distal diuretics in congestive heart failure.Nephrology, Dialysis, Transplantation 2024 Februrary 30
Efficacy and safety of pharmacotherapy in chronic insomnia: A review of clinical guidelines and case reports.Mental Health Clinician 2023 October
World Health Organization and International Consensus Classification of eosinophilic disorders: 2024 update on diagnosis, risk stratification, and management.American Journal of Hematology 2024 March 30
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app